ArticleBMC urology2026
Outcomes in patients undergoing benign prostatic hyperplasia surgical re-treatment with holmium laser enucleation of the prostate compared to treatment-naïve patients.
Article in BMC urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Tele-robot-assisted prostatectomy: the first systematic review and single-arm meta-analysis.Journal of robotic surgery · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMinimally invasive surgical therapies for benign prostatic hyperplasia (BPH) are increasingly utilized but may have limited long-term durability, leading some patients to require re-treatment. Holmium laser enucleation of the prostate (HoLEP) is a size-independent option, but outcomes after prior BPH intervention remain incompletely characterized. We compared perioperative, postoperative, and functional outcomes of HoLEP in re-treatment versus treatment-naïve HoLEP.
methodsWe performed a retrospective cohort study of patients undergoing HoLEP at a tertiary center between February 2021 and August 2025. Patients with prior surgical or minimally invasive BPH interventions were propensity score-matched 1:1 to treatment-naïve patients by prostate specimen weight. Perioperative variables, postoperative outcomes, and functional measures were compared.
resultsWe identified 418 re-treatment patients who were matched to 418 treatment-naïve controls. Re-treatment patients were older and had higher rates of prior urinary retention and urinary tract infection. Operative time, laser energy usage, and intraoperative complication rates were similar between cohorts. Overall, 90-day complication rates did not differ (6.5% vs. 5.5%, p = 0.66), though emergency department visits were more frequent in re-treatment patients (9.1% vs. 5.3%, p = 0.044). Both groups experienced comparable improvements in American Urological Association symptom and quality of life scores. Postoperative Michigan Incontinence Symptom Index severity scores were lower in the re-treatment cohort (4.9 ± 6.1 vs. 6.4 ± 6.5, p = 0.038).
conclusionsHoLEP performed after prior BPH intervention demonstrates perioperative safety and functional outcomes comparable to treatment-naïve HoLEP, supporting its role as a durable and effective treatment for recurrent or persistent BPH symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.